<DOC>
	<DOCNO>NCT00002247</DOCNO>
	<brief_summary>To compare safety tolerance oral ganciclovir double dose 3 times/day single dose 6 times/day IV ganciclovir give 20 week maintenance therapy . To compare time progression cytomegalovirus ( CMV ) retinitis two regimens oral ganciclovir IV ganciclovir therapy give 20 week maintenance therapy . To describe efficacy safety double dose versus single dose oral ganciclovir patient progression retinitis originally assign maintenance treatment . To describe safety , tolerance , time progression retinitis 52 week oral ganciclovir maintenance therapy people AIDS . To describe safety tolerance oral ganciclovir maintenance therapy give concurrently antiretroviral treatment ( e.g. , zidovudine , ddI , ddC ) . To describe survival people AIDS CMV retinitis .</brief_summary>
	<brief_title>A Randomized Study Comparing Safety Efficacy Two Regimens Oral Ganciclovir Intravenous Ganciclovir Maintenance Therapy Cytomegalovirus Retinitis People With AIDS Who Have Received Prior Ganciclovir Therapy</brief_title>
	<detailed_description>Two hundred twenty-five patient AIDS CMV retinitis eligible enrollment Groups A , B , C study , provide subject receive tolerated therapeutic course intravenous ( IV ) ganciclovir least 4 week duration result stable retinitis . An additional 100 subject receive tolerated course IV oral ganciclovir clinical trial oral ganciclovir sponsor Syntex Research stable retinitis may enter Group D study receive oral ganciclovir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine except first 2 week oral IV ganciclovir maintenance therapy . ddI . ddC . Patients must : Confirmed HIV infection diagnosis AIDS . CMV retinitis 4 month duration . Stable retinitis . Understanding nature study , agree provision , sign inform consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Persistent clinically significant diarrhea ( 3 unformed stools/day ) , nausea , abdominal pain gastrointestinal symptom uncontrolled gastrointestinal disease . Ocular medium opacity ( corneal , lenticular , vitreal ) prevent ophthalmologic retinal assessment . Ocular condition require immediate surgical correction ( e.g. , retinal tear detachment ) . Dementia , decrease mentation , encephalopathic sign symptom would interfere ability subject give inform consent comply protocol . Concurrent Medication : Excluded : Zidovudine first 2 week oral IV ganciclovir maintenance therapy . Antimetabolites . Alkylating agent . Selected nucleoside analog . Selected cytokine . Patients follow prior condition exclude : Diagnosis CMV retinitis 4 month prior study entry . More two prior induction treatment IV ganciclovir ( initial induction one reinduction permit ) . Prior Medication : Excluded : More two induction treatment regimens IV ganciclovir . Prior oral ganciclovir ( Groups A , B , C ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1993</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>